| abstract |
The present invention provides a novel pyrimidine compound having excellent adenosine receptor (A 1 , A 2A , A 2B receptor) antagonism. In detail, the compound represented by the following formula, its salt, or its solvate is provided.n n n n n n n n Expression from, R 1 and R 2 are C 2 that may have the same or different, a hydrogen atom, which may be in the substituted C 1-6 alkyl group, it may be a substituted C 2-6 alkenyl group, an optionally substituted -6 alkynyl group, C 3-8 cycloalkyl group which may have substituent, C 3-8 cycloalkenyl group which may have substituent, 5 to 14 membered non-aromatic heterocyclic group which may have substituent, substituent C 6-14 aromatic hydrocarbon cyclic group which may have, 5 to 14 membered aromatic heterocyclic group which may have substituent, C 1-6 acyl group which may have substituent, or C 1 which may have substituent -6 alkylsulfonyl group; R 3 is a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group which may have a substituent, a C 2-6 alkenyl group which may have a substituent, a C 2-6 alkynyl group which may have a substituent, A C 6-14 aromatic hydrocarboncyclic group which may have a substituent, a 5-14 membered aromatic heterocyclic group which may have a substituent, a nitrogen atom which may have a substituent, an oxygen atom which may have a substituent, or a substituent Represents a sulfur atom which may have a; R 4 is a C 6-14 aromatic hydrocarbon cyclic group which may have a substituent, a 5 to 14 membered aromatic heterocyclic group which may have a substituent, or 5 to 5 having at least one unsaturated bond which may have a substituent 14 membered non-aromatic heterocyclic group; R 5 represents a C 6-14 aromatic hydrocarbon cyclic group which may have a substituent or a 5 to 14 membered aromatic heterocyclic group which may have a substituent. |